Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.71 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.70 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.70 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.70 |
| ▸ | MAOB | P27338 | 3/20 | 0.66 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 3/20 | 0.62 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4199637 | 0.98 | PARP10 (0.69) | PARP10NR4A1NR4A2NR4A3MAOB | |
| SCHEMBL883145 | 0.91 | PARP10 (0.68) | PARP10NR4A1NR4A2NR4A3MAOB | |
| SCHEMBL2008979 | 0.85 | MAPK1 (0.56) | PARP10NR4A1NR4A2NR4A3MAOB | |
| SCHEMBL4220632 | 0.85 | NR4A1 (0.72) | PARP10NR4A1NR4A2NR4A3MAOB | |
| SCHEMBL1960673 | 0.85 | NR4A1 (0.72) | PARP10NR4A1NR4A2NR4A3MAOB | |
| SCHEMBL13238323 | 0.84 | SMN1; SMN2 (0.69) | PARP10MAOBPLA2G4BMAPTALDH1A1 | |
| SCHEMBL12987281 | 0.84 | MAOB (0.71) | PARP10NR4A1NR4A2NR4A3MAOB | |
| SCHEMBL4113161 | 0.83 | NR4A2 (0.70) | PARP10NR4A1NR4A2NR4A3MAOB | |
| SCHEMBL41220 | 0.83 | NR4A1 (0.70) | PARP10NR4A1NR4A2NR4A3MAOB | |
| SCHEMBL2686570 | 0.83 | NR4A1 (0.70) | PARP10NR4A1NR4A2NR4A3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | claimed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-7994315-B2 | Intermediate compound for synthesizing pharmaceutical agent and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| EP-2221305-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2221304-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
| EP-1384719-A1 | Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections | The Regents of The University of Michigan (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1196406-A1 | AMINO CERAMIDE-LIKE COMPOUNDS AND THERAPEUTIC METHODS OF USE | The Regents of the University of Michigan (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001004108-A1 | AMINO CERAMIDE-LIKE COMPOUNDS AND THERAPEUTIC METHODS OF USE | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2001-01-18 | — | — | WO | disclosed |
| EP-0255728-B1 | PHENOXYACETIC ACID COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE | TANABE SEIYAKU CO., LTD. (JP) | 1991-11-27 | — | — | EP | disclosed |
| US-4866196-A | ANTICOAGULANTS | TANABE SEIYAKU CO., LTD. (JP) | 1989-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | PARP10 630/4885NR4A1 733/4885NR4A2 900/4885 |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | PARP10 986/4885NR4A1 2936/4885NR4A2 3729/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | PARP10 630/4885NR4A1 733/4885NR4A2 900/4885 |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | PARP10 986/4885NR4A1 2936/4885NR4A2 3729/4885 |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | PARP10 2354/4885NR4A1 551/4885NR4A2 274/4885 |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | PARP10 986/4885NR4A1 2936/4885NR4A2 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.